⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639746 | 0.97 | SIGMAR1 (0.48) | — | |
| SCHEMBL4713746 | 0.97 | SIGMAR1 (0.48) | — | |
| SCHEMBL14519376 | 0.97 | SIGMAR1 (0.48) | — | |
| SCHEMBL14519375 | 0.97 | SIGMAR1 (0.48) | — | |
| SCHEMBL3819958 | 0.97 | SIGMAR1 (0.48) | — | |
| Fluoride SCHEMBL11231130 | 0.94 | SIGMAR1 (0.46) | — | |
| Ammonia Solution, Strong SCHEMBL16338366 | 0.94 | SIGMAR1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL2869749 | 0.94 | SIGMAR1 (0.46) | — | |
| Water SCHEMBL29083027 | 0.94 | SIGMAR1 (0.46) | — | |
| SCHEMBL2076710 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| WO-2000078826-A1 | CATALYSTS | BOREALIS TECHNOLOGY OY (FI) | 2000-12-28 | — | — | WO | claimed |
| EP-4328227-A1 | NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | Vigonvita Life Sciences Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113165892-B | Method for preparing SSZ-63 molecular sieve | 雪佛龙美国公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| CN-1902191-A | Amidopyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2007-01-24 | — | — | CN | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2000078826-A1 | CATALYSTS | BOREALIS TECHNOLOGY OY (FI) | 2000-12-28 | — | — | WO | disclosed |
| EP-1042336-A1 | PI-COMPLEX COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033852-A1 | π-COMPLEX COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |